Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 6:27 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 2,486 matching trials from the live ClinicalTrials.gov search.
Conditions
Solid Tumor, Solid Carcinoma, Solid Tumor, Adult, Metastatic Cancer, Advanced Solid Tumor, Cholangiocarcinoma, Bile Duct Cancer
Interventions
CF33-hNIS, Pembrolizumab, Modified FOLFOX
Biological · Drug
Lead sponsor
Imugene Limited
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
10
States / cities
Tucson, Arizona • Springdale, Arkansas • Duarte, California + 7 more
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
temozolomide
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2000
U.S. locations
2
States / cities
Fort Sam Houston, Texas • San Antonio, Texas
Conditions
Advanced Solid Tumor, Unresectable Solid Tumor, Metastatic Solid Tumor, Colorectal Adenocarcinoma, Pancreatic Adenocarcinoma, Lung Cancer, Ovarian Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma, Prostate Cancer, Bladder Cancer
Interventions
CLSP-1025
Drug
Lead sponsor
Clasp Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
21
States / cities
Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 14 more
Conditions
Cancer
Interventions
BMS-906024
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
6
States / cities
Los Angeles, California • Atlanta, Georgia • Detroit, Michigan + 3 more
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
oxaliplatin, leucovorin calcium, fluorouracil, capecitabine, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Liposarcoma, Prostate Cancer, Advanced Breast Cancer, NSCLC (Non-small Cell Lung Cancer), Colorectal Cancer
Interventions
PF-07220060, Letrozole, Fulvestrant, Midazolam, Enzalutamide, Giredestrant, Tamoxifen
Drug · Combination Product · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
14
States / cities
Los Angeles, California • New Haven, Connecticut • Trumbull, Connecticut + 5 more
Conditions
Cancer
Interventions
Antibody-Drug Conjugate
Drug
Lead sponsor
MBrace Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
17
States / cities
San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 13 more
Conditions
Solid Cancer
Interventions
cabazitaxel (XRP6258)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
7
States / cities
Los Angeles, California • San Diego, California • Decatur, Illinois + 4 more
Conditions
Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration, SCD1 Inhibitor MTI-301
Procedure · Other · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Jacksonville, Florida
Conditions
Advanced and/or Metastatic Solid Organ Cancer
Interventions
VB-111
Drug
Lead sponsor
Vascular Biogenics Ltd. operating as VBL Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
3
States / cities
Boston, Massachusetts • Cleveland, Ohio • San Antonio, Texas
Completed Phase 1 Interventional Results available

Phase I Combination Ixabepilone + Cisplatin

NCT00832117
Conditions
Non Small Cell Lung Cancer
Interventions
Ixabepilone, Cisplatin
Drug
Lead sponsor
R-Pharm
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
3
States / cities
Washington D.C., District of Columbia • New Brunswick, New Jersey • Hershey, Pennsylvania
Conditions
Lip and Oral Cavity Cancer, Head and Neck Cancer, Oropharyngeal Cancer
Interventions
cisplatin, fluorouracil, ONYX-015
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 79 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Advanced Solid Tumors
Interventions
PF-03758309
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Santa Monica, California • Aurora, Colorado
Conditions
Non-Small Cell Lung Cancer
Interventions
NKTR-214, Pembrolizumab, Cisplatin, Carboplatin, Nab paclitaxel, Paclitaxel, Pemetrexed, Atezolizumab
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
23
States / cities
Fayetteville, Arkansas • San Francisco, California • Aurora, Colorado + 19 more
Conditions
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage I Renal Cell Cancer, Stage II Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
sunitinib malate, bevacizumab, pharmacological study, laboratory biomarker analysis, fluorine F 18 fluorothymidine, positron emission tomography, computed tomography
Drug · Biological · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
2
States / cities
Baltimore, Maryland • Madison, Wisconsin
Conditions
Advanced Solid Tumor Malignancies
Interventions
OMP-305B83
Drug
Lead sponsor
OncoMed Pharmaceuticals, Inc.
Industry
Eligibility
21 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
4
States / cities
Scottsdale, Arizona • Aurora, Colorado • Ann Arbor, Michigan + 1 more
Conditions
Solid Tumor
Interventions
Phase I Arm A, Phase I Arm B
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
12
States / cities
La Jolla, California • Denver, Colorado • New Haven, Connecticut + 9 more
Conditions
Advanced Solid Tumor
Interventions
NB003 tablets
Drug
Lead sponsor
Ningbo Newbay Technology Development Co., Ltd
Industry
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
6
States / cities
Stanford, California • Jacksonville, Florida • Boston, Massachusetts + 3 more
Conditions
Advanced Solid Tumor
Interventions
OMTX705, Pembrolizumab, Tislelizumab (BGB-A317)
Drug
Lead sponsor
Oncomatryx Biopharma S.L.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Solid Tumor, Adult
Interventions
LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER, Pembrolizumab - anti-PD-1 antibody
Drug · Biological
Lead sponsor
Linnaeus Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
10
States / cities
Los Angeles, California • New Haven, Connecticut • Boston, Massachusetts + 5 more
Conditions
Metastatic Breast Cancer
Interventions
Capecitabine, Docetaxel
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Lebanon, New Hampshire
Conditions
Locally Advanced Solid Tumor, Metastatic Tumor, Colorectal Adenocarcinoma
Interventions
TST003
Drug
Lead sponsor
Transcenta Therapeutics (Hangzhou) Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
3
States / cities
Portland, Oregon • Dallas, Texas • San Antonio, Texas
Conditions
Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma, Pancreatic Carcinoma, Breast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 Negative, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Renal Cell Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Non-small Cell Lung Carcinoma, Small Cell Lung Cancer, Gastric or Gastroesophageal Junction Adenocarcinoma, Advanced Solid Tumors, Undifferentiated Pleomorphic Sarcoma
Interventions
XmAb®23104, Yervoy® (ipilimumab)
Biological
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
18
States / cities
San Diego, California • Aurora, Colorado • Denver, Colorado + 15 more
Conditions
Solid Tumor, Locally Advanced Solid Tumor, Metastatic Tumor
Interventions
5 Azacytidine, Pembrolizumab, Nivolumab, Cemiplimab
Drug
Lead sponsor
Mohammed Milhem
Other
Eligibility
18 Years to 99 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Iowa City, Iowa